Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non-small-cell lung cancerHERBST, Roy S; O'NEILL, Vincent J; FEHRENBACHER, Louis et al.Journal of clinical oncology. 2007, Vol 25, Num 30, pp 4743-4750, issn 0732-183X, 8 p.Article

TRIBUTA: A phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancerHERBST, Roy S; PRAGER, Diane; RAMIES, David et al.Journal of clinical oncology. 2005, Vol 23, Num 25, pp 5892-5899, issn 0732-183X, 8 p.Article

Phase I trial of irinotecan, infusional 5-fluorouracil, and leucovorin (FOLFIRI) with erlotinib (OSI-774): Early termination due to increased toxicitiesMESSERSMITH, Wells A; LAHERU, Daniel A; SENZER, Neil N et al.Clinical cancer research. 2004, Vol 10, Num 19, pp 6522-6527, issn 1078-0432, 6 p.Article

Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancerHERBST, Roy S; JOHNSON, David H; HONG, Waun K et al.Journal of clinical oncology. 2005, Vol 23, Num 11, pp 2544-2555, issn 0732-183X, 12 p.Conference Paper

Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinibEBERHARD, David A; JOHNSON, Bruce E; KLEIN, Pam et al.Journal of clinical oncology. 2005, Vol 23, Num 25, pp 5900-5909, issn 0732-183X, 10 p.Article